Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC
Status:
RECRUITING
Trial end date:
2030-01-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, double-blind, placebo-controlled randomized phase II study to assess whether continuation of cemiplimab treatment (for up to 12 months) increases progression-free survival (PFS) as compared to placebo in patients with a stage IV, synchronous, oligometastatic non-small cell lung cancer (NSCLC) who have not progressed following 4 cycles of cemiplimab with our without platinum-based chemotherapy and radical treatment.
Eligible patients are randomized with a 1:1 ratio to either the cemiplimab or placebo group and will undergo disease assessment (e.g. imaging, blood tests) at regular follow-up visits.
Phase:
PHASE2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC